BaiyaPharming™ — turns plants into precision protein factories
Our proprietary platform uses Nicotiana benthamiana as a living bioreactor to produce biologics — with the speed, flexibility, and quality that conventional manufacturing cannot match.
Why plant-based?
Conventional biopharmaceutical manufacturing relies on mammalian cell lines or microbial systems that require months of development, expensive bioreactor infrastructure, and long lead times. When a new pathogen emerges or a partner needs a novel protein fast, conventional systems simply cannot respond quickly enough.
BaiyaPharming™ changes this. By using plants as the production host, we compress development timelines from months to weeks — without sacrificing quality, safety, or regulatory compliance.
Conventional biologics manufacturing
- Cell line development takes 6–18 months
- High capital cost for bioreactor infrastructure
- Limited scalability during emergencies
- Long lead times from sequence to clinical material
- Complex upstream development requirements
BaiyaPharming™ platform
- Gene sequence to purified protein in weeks
- Significantly lower capital and operating costs
- Rapid greenhouse scale-up for pandemic response
- Human-compatible glycosylation profiles
- Proven at clinical scale — COVID-19 Phase 1 trial
How it works
Speed and cost advantage
The BaiyaPharming™ platform consistently outperforms conventional systems on the metrics that matter most to our partners — time, cost, and flexibility.